AC Immune SA (ACIU) Hits Safety, Immunogenicity Goals in Phase 2 Part 1

AC Immune said Part 1 of its Phase 2 VacSYn trial in early Parkinson’s met safety, tolerability and immunogenicity endpoints, with 100% of treated patients generating antibodies and CSF penetration observed. Part 2 design will be submitted to the FDA, with meetings expected early 2027.Material Deta…